Chongqing Genrix Biopharmaceutical Co., Ltd. announced its investigational drug Sleridimab Injection has received clinical trial authorization from regulatory authorities. This monoclonal antibody therapy advances the company's immunology pipeline targeting autoimmune disorders. The Shanghai-listed biopharmaceutical firm specializes in novel antibody development with multiple candidates in preclinical and clinical stages. Approval enables Phase 1 human trials evaluating safety and pharmacokinetics. This milestone follows Genrix's strategic focus on innovative biologics addressing unmet medical needs across inflammatory and oncological indications. No trial timelines or specific indications were disclosed in the regulatory filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。